The COVID-19 pandemic has had a severe impact on health services across the EU and one public health condition that was sidelined, among others, was Alzheimer’s disease.
The World Health Organisation (WHO) has spotted serious malfunctioning in dementia diagnosis and assessment.
According to the WHO, it is estimated that the crude prevalence of dementia in those aged 65+ is 8.5%, or 13.1 million (population over 65 years in the WHO European Region is 154.3 million).
Stakeholders caution that urgent and coordinated action is needed to help EU patients and their carers cope with the challenges of Alzheimer’s disease.
Meanwhile, promising new technologies and innovative therapies in the field are constantly emerging, which patients want to take full advantage of.
The COVID-19 pandemic has had and will continue to have a negative impact on people suffering from dementia, Dr Natasha Azzopardi Muscat from the World Health Organisation (WHO) told EURACTIV in an interview.
“I will eventually have the luxury of forgetting, all those around me won’t have that luxury, they will never forget what dementia has done to us,” Chris Roberts, who has dementia, told EURACTIV.com in an interview, emphasising the need for increased awareness over a devastating disease is present in all corners of the world.
Patient involvement in research on dementia has shown to be mutually beneficial, both to the quality of medical studies and to people’s rights to be involved in relevant research about their own condition, according to health experts.
By taking concrete steps today, Europe can be prepared for Alzheimer’s disease (AD). The burden of disease is growing, so there is no time to wait.
The COVID-19 pandemic has brought the need for health system readiness into sharp focus. It …
Transposing research outcomes into digital products and services is a complex but stimulating process that could move the needle in diagnosing Alzheimer early but also in improving the quality of life of patients.